Literature DB >> 12200670

CD34(+) or CD34(-): which is the more primitive?

M Engelhardt1, M Lübbert, Y Guo.   

Abstract

Remarkable progress has been achieved in the characterization and isolation of primitive hematopoietic stem cells (HSC). HSC represent a very small subset of hematopoietic cells and provide self-renewal, possess differentiation capacity and allow a constant supply of the entire hematopoietic cell spectrum. Until recently, CD34 has been used as a convenient marker for HSC, since CD34(+) cells have been shown to possess colony-forming potential in short-term assays, maintain long-term colony-forming potential in in vitro cultures and allow the expression and differentiation of blood cells from different hematopoietic lineages in in vivo models. Clinical and experimental protocols have targeted CD34(+) cells enriched by a variety of selection models and have readily used these for transplantation, purging and gene therapies and targets for future organ replacement. Recent studies in murine and human models, however, have indicated that CD34(-) HSC exist as well, which possess engraftment potential and distinct HSC characteristics. These studies challenge the dogma that HSC are uniformly found in the CD34(+) subset, and question whether primitive HSC are CD34(+) or CD34(-). In this review, results on murine and human CD34(+) and CD34(-) HSC, differences between them and their possible interactions are examined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200670     DOI: 10.1038/sj.leu.2402620

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Ensheathing cell-conditioned medium directs the differentiation of human umbilical cord blood cells into aldynoglial phenotype cells.

Authors:  María Dolores Ponce-Regalado; Daniel Ortuño-Sahagún; Carlos Beas Zarate; Graciela Gudiño-Cabrera
Journal:  Hum Cell       Date:  2012-04-21       Impact factor: 4.174

2.  Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells.

Authors:  Jean-François Mayol; Corinne Loeuillet; Francis Hérodin; Didier Wion
Journal:  Bioessays       Date:  2009-09       Impact factor: 4.345

3.  Hematopoietic stem cells in research and clinical applications: The "CD34 issue".

Authors:  Zoran Ivanovic
Journal:  World J Stem Cells       Date:  2010-04-26       Impact factor: 5.326

Review 4.  Alcohol abuse and disorder of granulopoiesis.

Authors:  Xin Shi; Angelo L DeLucia; Jianxin Bao; Ping Zhang
Journal:  Pharmacol Ther       Date:  2019-03-01       Impact factor: 12.310

Review 5.  Epigenetic gene regulation in stem cells and correlation to cancer.

Authors:  Lesley A Mathews; Francesco Crea; W L Farrar
Journal:  Differentiation       Date:  2009-05-14       Impact factor: 3.880

6.  PADI4 and tumourigenesis.

Authors:  Xiaotian Chang; Kehua Fang
Journal:  Cancer Cell Int       Date:  2010-03-12       Impact factor: 5.722

7.  Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging.

Authors:  Claudia E Rübe; Andreas Fricke; Thomas A Widmann; Tobias Fürst; Henning Madry; Michael Pfreundschuh; Christian Rübe
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

8.  Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis.

Authors:  Kazunori Nakase; Kenkichi Kita; Taiichi Kyo; Takanori Ueda; Isao Tanaka; Naoyuki Katayama
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

9.  ELF-MF exposure affects the robustness of epigenetic programming during granulopoiesis.

Authors:  Melissa Manser; Mohamad R Abdul Sater; Christoph D Schmid; Faiza Noreen; Manuel Murbach; Niels Kuster; David Schuermann; Primo Schär
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

10.  Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device.

Authors:  Joel C Wojciechowski; Srinivas D Narasipura; Nichola Charles; Deanne Mickelsen; Kuldeeepsinh Rana; Martha L Blair; Michael R King
Journal:  Br J Haematol       Date:  2008-01-22       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.